R1498 is an inhibitor of cyclin-dependent kinase 2. It also acts by targeting angiogenesis and mitosis pathways. It is well-tolerated and orally active for hepatocellular carcinoma and gastric cancer treatment.
MMAE-SMCC is a drug-linker conjugate designed for antibody-drug conjugates (ADC). It consists of MMAE, a potent inhibitor of mitosis and tubulin, and SMCC, a linker that facilitates the development of ADCs.